BioSpace News Archive

Fasciotomy is a surgical procedure for patients suffering from compartment syndrome, carried out to relieve the pressure or tension in the muscles.

Ultrasound transducers are systems used to evaluate targets and interpret the reflected signals. Ultrasound transducers are available in different shapes and sizes which produces an image in the form of a plane body with the structures cut across.

Gas blending is the procedure of precise mixing of different gases for a medical or non-medical purpose in a controlled environment.

Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, announced that David Hering has been appointed as the company’s chief operating officer.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development.

OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Clinical Laserthermia Systems AB, developer of high precision, image-guided focal laser ablation systems, announced that a review article titled “Local Destruction of Tumors and Systemic Immune Effects” has been published in the Journal “Frontiers in Oncology” by the company’s co-founder and Senior Clinical Advisor, Professor Karl-Göran Tranberg.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the appointment of Carolyn E. Taylor to its Board of Directors, effective as of July 16, 2021.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, announced that the first patient had been dosed in its Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigmentosa.

Immunomic Therapeutics, Inc. announced today that it has appointed Robert Newman as Chief Business Officer.